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Abstract
Background: Pleiotrophin, also known as HARP (Heparin Affin Regulatory Peptide) is a growth factor expressed in
various tissues and cell lines. Pleiotrophin participates in multiple biological actions including the induction of
cellular proliferation, migration and angiogenesis, and is involved in carcinogenesis. Recently, we identified and
characterized several pleiotrophin proteolytic fragments with biological activities similar or opposite to that of
pleiotrophin. Here, we investigated the biological actions of P(122-131), a synthetic peptide corresponding to the
carboxy terminal region of this growth factor.
Results: Our results show that P(122-131) inhibits in vitro adhesion, anchorage-independent proliferation, and
migration of DU145 and LNCaP cells, which express pleiotrophin and its receptor RPTPb/ζ. In addition, P(122-131)
inhibits angiogenesis in vivo, as determined by the chicken embryo CAM assay. Investigation of the transduction
mechanisms revealed that P(122-131) reduces the phosphorylation levels of Src, Pten, Fak, and Erk
1/2. Finally, P(122-
131) not only interacts with RPTPb/ζ, but also interferes with other pleiotrophin receptors, as demonstrated by
selective knockdown of pleiotrophin or RPTPb/ζ expression with the RNAi technology.
Conclusions: In conclusion, our results demonstrate that P(122-131) inhibits biological activities that are related to
the induction of a transformed phenotype in PCa cells, by interacing with RPTPb/ζ and interfering with other
pleiotrophin receptors. Cumulatively, these results indicate that P(122-131) may be a potential anticancer agent,
and they warrant further study of this peptide.
Background
Pleiotrophin, also known as HARP (Heparin Affin Regu-
latory Peptide) is a 136-amino acid, secreted growth fac-
tor that, along with Midkine, constitutes a two-member
sub family of heparin binding growth factors (HBGFs).
Although pleiotrophin has been shown to promote
neurite outgrowth in the developing brain [1], elevated
concentrations of this growth factor are found in many
types of tumors as well as in the plasma of patients with
different types of cancer [2-4]. Pleiotrophin induces a
transformed phenotype in several cell lines [5,6] and
exhibits mitogenic, anti apoptotic, chemotactic, and
angiogenic actions in vitro as well as in vivo [7-10].
The biological activities of pleiotrophin are mediated
by three distinct receptors: SDC3 (N-Syndecan) [11],
Receptor Protein Tyrosine Phosphatase (RPTPb/ζ) [12],
and Anaplastic Lymphoma Kinase (ALK) [13]. N-Synde-
can and RPTPb/ζ have been implicated in neurite out-
growth [10,11], while RPTPb/ζ and ALK have been
shown to mediate cellular migration induced by pleio-
trophin as well as the mitogenic, angiogenic, and trans-
forming activities of this growth factor [14-18].
Growth factors can be hydrolyzed by proteases, lead-
ing to the production of biological active peptides. Pre-
vious studies indicate that pleiotrophin is cleaved by
enzymes in the extracellular environment, such as plas-
min, trypsin, chymotrypsin, and MMPs. Moreover, the
resulting peptides exert altered biological functions
compared to the whole molecule. The proteolytic clea-
vage of pleiotrophin is also affected by the presence of
glycosaminoglycans (GAGs), suggesting that a complex
system serves to regulate the overall effect of this
growth factor [19,20]. Furthermore, pleiotrophin and
pleiotrophin peptides modulate the biological actions of
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complex mode of growth factor actions [21].
Prostate cancer (PCa) is the most common cancer
among men in Western countries, although the develop-
m e n to fP C aa sw e l la st h es i g n a l sc o n t r i b u t i n gt ot h e
transformed phenotype of PCa cells remains incomple-
tely understood [22]. During adulthood, maintenance of
normal prostate function depends on mesenchymal-
epithelial interactions, which contribute to the homeo-
static equilibrium of the glandular prostate epithelial
cells. Disturbances in this equilibrium lead to the devel-
opment of diseases like PCa. Although the mechanisms
that control the mesenchymal-epithelial interactions are
poorly understood, numerous studies suggest that
growth factors have a key role in prostate homeostasis.
Pleiotrophin has been implicated in PCa progression
and acts as an autocrine growth factor in various pros-
tate-derived cell lines including DU145, PC3, and
LNCaP [23,24].
Truncated forms of pleiotrophin or synthetic peptides
corresponding to defined domains of this growth factor
have been studied in an attempt to understand the
structure/function relationship of pleiotrophin [25-27].
We previously reported that the biological effects of this
growth factor were inhibited by the truncated mutant
PTNΔ111-136 and corresponding synthetic peptide P
(111-136) [28]. In the context of defining peptides with
anti tumor actions, we sought to identify the minimum
sequence responsible for the inhibition of pleiotrophin
activity. Since an obvious feature of P(111-136) is the
stretch of basic residues, we investigated whether the
basic sequence P(122-131) (KKKKKEGKKQ) may have
biological activities that are related to the induction of a
transformed phenotype in PCa cells. Here, we investi-
gated the effect of P(122-131) on the adhesion, prolifera-
tion, and migration of two prostate epithelial cell lines
as well as on in vivo angiogenesis.
Results
In a previous work, we reported that P(122-131) inhibits
anchorage-independent growth of DU145 prostate cancer
cells [29]. In the present work, we tested the effect of P
(122-131) on other tumor phenotypes in the well-estab-
lished prostate carcinoma cell lines, DU145 and LNCaP.
We also investigated the effect of these peptides on
angiogenesis in vivo, using the CAM assay. Since P(122-
131) contains seven lysines and is highly charged, we also
examined the effects of two “mock” peptides in parallel.
One consisted of D-amino acids (designated AAD), while
the other consisted of five lysines (designated 5K).
P(122-131) inhibits adhesion of DU145 and LNCaP cells
The effect of P(122-131) on the adhesion of DU145 cells
was tested using three approaches. First, an equal
number of cells was incubated with increasing concen-
trations of peptides and immediately seeded. In the sec-
ond approach, cells were incubated with different
concentrations of the peptides for 30 min before seed-
ing. In the final approach, cells were pre-incubated for
30 min with increasing concentrations of peptide, then
washed and seeded. After a 10-min incubation period,
adherent cells were measured by the crystal violet assay.
Under all conditions, P(122-131) inhibited adhesion in a
concentration dependent manner, having a maximal
effect (50% inhibition relative to control) at a concentra-
tion of 20 μΜ (Figure 1A). To confirm this result, we
looked for inhibitory effect of P(122-131) on the adhe-
sion of LNCaP cells. As shown in Figure 1A, P(122-131)
inhibited LNCaP adhesion in a concentration-dependent
manner, having a maximal effect (40% inhibition relative
to control) at a concentration of 20 μΜ.
P(122-131) inhibits anchorage-independent proliferation
of DU145 and LNCaP cells
The effect of P(122-131) on the proliferation of DU145
and LNCaP cells was investigated. We found that P
(122-131) inhibited anchorage-independent proliferation
in a concentration-dependent manner, having a maximal
effect (60% inhibition relative to control) at a concentra-
tion of 20 μΜ (Figure 1B).
P(122-131) inhibits migration of DU145 and LNCaP cells
We next investigated the effect of P(122-131) on DU145
and LNCaP chemotaxis, as measured using Transwell
assays. Similar to its effects on adhesion and prolifera-
tion, P(122-131) inhibited chemotactic migration in a
concentration-dependent manner (55% inhibition rela-
tive to control). The maximal effect was observed at the
concentration of 20 μM (Figure 1C).
P(122-131) inhibits the in vivo angiogenesis
The inhibitory effects of P(122-131) on DU145 and
LNCaP adhesion, proliferation, and migration are
consistent with a possible anti-tumor action for this
peptide. Therefore, we tested the effect of this peptide
on in vivo angiogenesis. Tumor angiogenesis plays a
key role in cell proliferation by providing nutrients and
oxygen. It also facilitates metastasis through the forma-
tion of new, leaky vessels. We observed that P(122-
131) reduced the total length of blood vessels in the
CAM assay in a concentration-dependent manner.
Angiogenesis was inhibited up to 45%, with maximal
inhibition occurring in the presence of 2 nmol P(122-
131) (Figure 1D).
In contrast to P(122-131), neither AAD nor 5K had
any measurable effect on angiogenesis. Similarly, neither
affected adhesion, proliferation, nor migration of DU145
or LNCaP cells (Figure 2).
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P(122-131) harbours a cluster of basic residues known
to bind to cell receptors [25]. To begin to understand
the mechanism through which P(122-131) exerts its bio-
logical actions, we investigated the effect of this peptide
on signaling mediated by the pleiotrophin receptors. In
a previous work, co-immunoprecipitation/Western blot
analysis of P(122-131) and RPTPb/ζ indicated that this
pleiotrophin receptor interacts with P(122-131) [29]. To
provide additional support for an interaction between P
(122-131) and RPTPb/ζ, DU145 cells were co-labelled
for B(122-131) and RPTPb/ζ.A f t e ra3 0 - s e ci n c u b a t i o n
of cells with B(122-131), confocal microscopy revealed B
(122-131) bound to the cell surface and co-localized
with RPTPb/ζ (Figure 3A). After a 20-min incubation,
endocytotic vesicles containing both B(122-131) and
Figure 1 P(122-131) promotes anti-tumor phenotypes in DU145 and LNCaP cells and inhibits angiogenesis in vivo.( A )N u m b e ro f
adherent DU145 and LNCaP cells in the presence of increasing concentrations of P(122-131). An equal number of DU145 or LNCaP cells was
incubated with increasing concentrations of P(122-131) for 30 min before seeding. After a 10-min incubation period, adherent cells were
measured by the crystal violet assay. (B) Soft agar growth assays showing anchorage-independent proliferation. An equal number of DU145 or
LNCaP cells was resuspended in growth medium containing 10% FBS, 0.3% agar, and increasing concentrations of P(122-131), and seeded onto
the bottom agar, which consisted of growth medium containing 10% FBS and 0.8% agar. The top agar was allowed to solidify, and standard
growth media supplemented with peptide was added to each well. The cells were incubated 12 days, after which cell colonies larger than
50 μm were quantified by counting the entire area of each well. (C) Migration of cells through Transwell filters. The lower compartment of
Transwell filters (8 μm pores) was filled with growth media containing 2.5% FBS, 0.5% BSA, and increasing concentrations of P(122-131). An equal
number of DU145 or LNCaP cells was resuspended in growth medium containing 2.5% FBS and 0.5% BSA, and transferred into Transwell inserts.
Cells that successfully migrated through the filter pores, were fixed, stained and quantified by counting the entire area of each filter. (D) Effect of
P(122-131) on angiogenesis, as measured by the chicken embryo CAM assay. An 1 cm
2 area of chicken embryo CAM, restricted by a silicon ring,
was incubated with increasing concentrations of P(122-131). 48 h later total vessels length was quantified as described in Materials and Methods.
Results are mean values ± SE from at least 3 independent experiments.
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Furthermore, as shown in Figure 3C, P(122-131) asso-
ciation with RPTPb/ζ was displaced by pleiotrophin. As
expected, incubation of cells with only streptavidin-
FITC or rhodamine conjugated secondary antibodies
produced no signal (data not shown).
Elucidation of the mechanism through which P(122-131)
exerts its biological actions
DU145 and LNCaP cells synthesize and secrete pleiotro-
phin, which in an autocrine manner stimulates cells
[3,24]. To examine whether the inhibitory effects of P
(122-131) on DU145 adhesion, proliferation, and migra-
tion may be the result of endogenous pleiotrophin inhi-
bition, we stably transfected DU145 cells with
pcDNA3.1+ plasmid encoded the antisense mRNA of
pleiotrophin. After 1 month of selection with neomycin,
clones were screened for down-regulation of
pleiotrophin expression. Strong down-regulation of
pleiotrophin expression was observed in clones #2 and
#5 (DU145-HM2 and DU145-HM5 respectively). No
reduction of the pleiotrophin expression was observed
in cells transfected with pcDNA3.1+ alone (DU145-
NC1, DU145-NC3) (Additional file 1-A).
As shown in Figure 4A, pleiotrophin knockdown
decreased DU145 adhesion, and P(122-131) further
decreased it. However, the inhibitory effect of P(122-131)
on the adhesion of DU145-HM2 cells was up to 20%,
while its inhibitory effect on DU145 adhesion was up to
50%. No difference between the adhesion of DU145 and
DU145-NC3 cells was observed (data not shown). These
results indicate that P(122-131) not only inhibits pleio-
trophin-mediated adhesion, but also may interfere with
other growth factors actions. Furthermore, since pleiotro-
phin enforces dimerization of RPTPb/ζ, inactivates its
catalytic activity [30], and inhibits cellular adhesion
Figure 2 P(122-131) inhibitory effect is attributed to its specific amino acid sequence and charge. (A) Number of adherent DU145 and
LNCaP cells in the presence of 20 μM P(122-131), AAD, or 5K, as determined by the crystal violet assay. (B) Soft agar growth assays showing
anchorage-independent proliferation. (C) Migration of cells through Transwell filters. (D) Effect of 2 nmol P(122-131), AAD, or 5K on angiogenesis
as measured by the chicken embryo CAM assay. Results are mean values ± SE from at least 3 independent experiments.
Diamantopoulou et al. Molecular Cancer 2010, 9:224
http://www.molecular-cancer.com/content/9/1/224
Page 4 of 13(unpublished data), the inhibitory effect of P(122-131)
may also be the result of its interaction with RPTPb/ζ.
To examine whether RPTPb/ζ mediates the inhibitory
effect of P(122-131), we tested the effect of P(122-131)
on DU145 cells with stable down-regulation of RPTPb/ζ
expression (DU145-RM6). We found that P(122-131)
inhibits DU145-RM6 adhesion up to 20% (Figure 4A),
indicating that the peptide interferes with other pleiotro-
phin receptors or with other growth factors. To deter-
mine whether P(122-131) may interfere with other
growth factors, we transiently transfected DU145-HM2
cells with a siRNA targeting the mRNA of RPTPb/ζ.I n
parallel, DU145-HM2 cells were transiently transfected
with a siRNA that does not target any mRNA (negative
control) (Additional file 1-B). As shown in Figure 4A,
pleiotrophin/RPTPb/ζ knockdown decreased DU145
adhesion, and blocked the inhibitory effect of P(122-131).
No difference between the adhesion of DU145-HM2 and
DU145-HM2 cells transfected with the negative control
siRNA was observed (data not shown). Taken together,
Figure 3 P(122-131) binds to RPTPb/ζ. Merged images of overlapping co-labelling for biotinylated P(122-131), [B(122-131)] (green) and RPTPb/
ζ (red). Incubation of DU145 cells with B(122-131) for 30 sec (A) or for 20 min (B). Incubation of DU145 cells with B(122-131) and pleiotrophin
for 20 min (C). Overlapping labelling appears yellow. B(122-131) was visualized using streptavidin-FITC, while RPTPb/ζ using specific monoclonal
antibody and rhodamine conjugated secondary antibody.
Figure 4 Elucidation of the mechanism through which P(122-131) exerts its biological actions. Effect of P(122-131) on adhesion (A),
anchorage-independent proliferation (B), and migration (C) of DU145, DU145-HM2, and DU145-RM6 cells. DU145-HM2 cells transfected with
pleiotrophin antisense RNA, DU145-RM6 cells transfected with shRNA targeting RPTPb/ζ. The last two bars of each diagram indicate DU145-HM2
cells that were transiently transfected with siRNA targeting RPTPb/ζ. Results are mean values ± SE from at least 3 independent experiments.
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RPTPb/ζ and induces RPTPb/ζ inhibitory effect on cellu-
lar adhesion, while in parallel antagonizes the interaction
of pleiotrophin with its other receptors, probably SDC3,
inhibiting pleiotrophin-induced adhesion.
As shown in Figure 4B, pleiotrophin knockdown
decreased DU145 anchorage-independent proliferation,
and P(122-131) further decreased it. However, the inhi-
bitory effect of P(122-131) on this biological action was
not as effective as on wild type cells. These results indi-
cate that P(122-131) interferes with pleiotrophin and
other growth factors actions. However, the effect of
RPTPb/ζ knockdown on the formation of cell colonies
was so strong that we cannot draw any conclusion
about the mechanism that P(122-131) inhibits ancho-
rage-independent proliferation.
A ss h o w ni nF i g u r e4 C ,p l e i o t r o p h i nk n o c k d o w n
decreased DU145 chemotactic migration, and P(122-131)
further decreased it. However, the inhibitory effect of P
(122-131) on the migration of DU145-HM2 cells was up
to 20%, while its inhibitory effect on DU145 migration was
up to 55%. No difference between the migration of DU145
and DU145-NC3 cells was observed (data not shown).
These results indicate that P(122-131) not only inhibits
pleiotrophin-mediated migration, but also may interfere
with other growth factors signaling. Furthermore, since
pleiotrophin enforces dimerization of RPTPb/ζ,i n a c t i v a t e s
its catalytic activity [30], and inhibits cellular migration
(unpublished data), the inhibitory effect of P(122-131) may
also be the result of its interaction with RPTPb/ζ.T o
examine whether RPTPb/ζ mediates the inhibitory effect
of P(122-131), we tested the effect of P(122-131) on
DU145-RM6 cells. We found that P(122-131) inhibits
DU145-RM6 migration up to 20% (Figure 4C), indicating
that the peptide interferes with other pleiotrophin recep-
tors or with other growth factors. To determine whether P
(122-131) may interfere with other growth factors, we
examined its effect on cells in which both pleiotrophin
and RPTPb/ζ expression was down-regulated. As shown
in Figure 4C, pleiotrophin/RPTPb/ζ knockdown decreased
DU145 migration, and blocked the inhibitory effect of P
(122-131). No difference between the migration of
DU145-HM2 and DU145-HM2 cells transfected with the
negative control siRNA was observed (data not shown).
Taken together, these results indicate that P(122-131)
interacts with RPTPb/ζ and induces RPTPb/ζ inhibitory
effect on cellular migration, while in parallel antagonizes
the interaction of pleiotrophin with its others receptors,
probably SDC3, inhibiting pleiotrophin-induced migration.
P(122-131) inactivates Src, Fak, and Erk
1/2, and activates
Pten
Src activation is strictly regulated and depends on
dephosphorylation of Y527 in the carboxy-terminal tail,
which is prerequisite for its subsequent activation by
autophosphorylation of Y416 in the activation loop of
t h ek i n a s e[ 3 1 ] .T od e t e r m i n ew h e t h e rS r cm a yb e
affected by P(122-131), DU145 cells were serum starved
for 4 h, then incubated with increasing concentrations
of P(122-131) for 3 to 45 min. Src inactivation was
indirectly assessed by Western blot analysis of phos-
phorylated Src at site Y416 and HSC70 that was used to
normalize the results. As shown in Figure 5A, P(122-
131) promoted a swift decrease in Src phosphorylation
within 3 min in a concentration dependent manner,
having a maximal effect (70% inhibition relative to con-
t r o l )a tac o n c e n t r a t i o no f2 0μΜ. This inactivation
returned to near basal levels by 45 min (Figure 5A).
We next investigated the effects of P(122-131) on
inactivation of other molecules known to interact with
Src. We found that FAK phosphorylation was decreased
15 min after incubation of DU145 cells with P(122-131)
in a concentration dependent manner, having a maximal
effect (70% inhibition relative to control) at a concentra-
tion of 20 μΜ. This inactivation returned to near basal
l e v e l sb y4 5m i n( F i g u r e5 C ) .A ss h o w ni nF i g u r e5 D ,
ERK
1/2 were also inactivated after a 15-min incubation
with P(122-131) that was sustained up to 45 min (70%
inhibition relative to control). Finally, PTEN was acti-
vated after a 15-min incubation with P(122-131) that
was sustained up to 45 min (80% inhibition relative to
control) (Figure 5B).
Elucidation of the mechanism through which P(122-131)
affects Src, Fak, Pten, and Erk
1/2 activity
I nap r e v i o u ss t u d y ,w eh a v es h o w nt h a tp l e i o t r o p h i n
enforces RPTPb/ζ dimerization and inactivation, and
reduces the phosphorylation levels of Src, Fak, Pten, and
Erk
1/2 (unpublished data). In this study, we showed that
P(122-131) interacts with RPTPb/ζ and induces RPTPb/
ζ inhibitory effect on cellular adhesion and migration,
while in parallel antagonizes the interaction of pleiotro-
phin with its others receptors, probably SDC3, inhibiting
pleiotrophin-induced biological actions. To confirm that
P(122-131) interferes with pleiotrophin signaling, we
tested its effect on activation of Src, Fak, Pten, and
ERK
1/2 of DU145-HM2 cells. As shown in Figure 6A,
the phosphorylation levels of Src, Fak, Pten, and Erk
1/2
are induced on DU145-HM2 cells compared with wild
type cells, while pleiotrophin knockdown partially
blocked P(122-131)-induced Src, Fak and Erk
1/2 inacti-
vation, and Pten activation. Since pleiotrophin expres-
sion levels are low on DU145-HM2 cells, RPTPb/ζ
cannot be dimerized, and as monomer reduces the
phosphorylation of Src at site Y527 and induces autop-
hosphorylation of Y416, resulting in increased Fak, Pten,
and Erk
1/2 phosphorylation. However, when DU145-
HM2 cells are treated with P(122-131), it cannot inhibit
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tion levels of Src, Fak, Pten, and Erk
1/2 through RPTPb/
ζ. Furthermore, as shown in Figure 6B, RTPPb/ζ knock-
down partially blocked P(122-131)-mediated Src and
Fak inactivation, and inhibited P(122-131)-mediated
Pten activation and Erk
1/2 inactivation. Taken together,
these results indicate that P(122-131)/RPTPb/ζ interac-
tion triggers a signal transduction pathway that reduces
the phosphorylation levels of these four signal transduc-
tion molecules, and inhibits cellular adhesion and migra-
tion, while in parallel P(122-131) interferes with other
pleiotrophin receptors, probably SDC3, inhibits pleiotro-
phin-mediated Src and Fak activation, resulting in inhi-
bition of pleiotrophin-induced cellular adhesion and
migration.
Discussion
During the last decade, pleiotrophin has come to be
recognized as a pleiotropic growth factor that partici-
pates not only in neurite outgrowth in the developing
brain [1], but also in angiogenesis, and malignant trans-
formation of many cell types. Pleiotrophin is elevated in
sera or tumors from patients with colon, stomach, pan-
creatic, and breast cancer [2-10]. Moreover, the
differential expression of pleiotrophin mRNA and pro-
tein among normal and malignant prostate epithelial
cells, implicates this protein in the induction of a trans-
formed phenotype [24].
NMR studies showed that pleiotrophin contains two
b-sheet domains connected by a flexible linker. In addi-
tion, its two lysine cluster sequences within both the N-
and C-terminal domains lack a detectable structure and
appear to form random coils [32]. To date, pleiotrophin
activities have been attributed either to the entire mole-
cule or to specific domains. From previous studies, it is
known that either but not both the N- or C-terminal
domains is required for pleiotrophin activity [27], and
that the C-terminal domain is involved in the mitogenic,
angiogenic, and tumor formation activities of this
growth factor [25,28]. Furthermore, pleiotrophin peptide
fragments have been detected in cell supernatants, as
well as in tissues [33,34], and such peptides can also be
generated in vitro by proteolytic cleavage of pleiotrophin
[20]. Our group has already characterized the biological
actions of several pleiotrophin peptides [10,20,25,28]. It
is noteworthy, that although pleiotrophin N- and C-
terminal domains lack a detectable structure, peptides
corresponding to these domains induce in vitro and in
Figure 5 Src, Fak, and Erk
1/2 are inactivated by P(122-131), while PTEN is activated. Western blot analysis of phosphorylated Src(A), Fak (B)
Pten (C), and Erk
1/2 (D), in cells stimulated with increasing concentrations of P(122-131) for 3, 15, and 45 minutes. The blots were stripped and
reprobed for HSC70. Results are expressed as % change relative to control and are mean values ± SE from at least 3 independent experiments.
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actions of pleiotrophin should be always considered to
be the overall outcome of its secretion, degradation, and
specific cleavage, with latter event possibly generating
pleiotrophin peptides with diverse, or even opposite,
biological actions. To illustrate this point, a study on
glioblastoma cell proliferation and migration has
revealed that cleavage of the 12 C-terminal amino acids
from pleiotrophin (124-136) leads to distinct biological
activities through differential activation of RPTPb/ζ or
ALK signalling pathways [15].
In this study, we sought to identify the minimum
sequence of the C-terminal region of pleiotrophin that
is responsible for the inhibition of biological activities
that are related to the induction of a transformed phe-
notype in PCa cells. Since an obvious feature of pleio-
trophin C-terminal domain is the stretch of basic
residues, we investigated the effect of the basic sequence
P(122-131) (KKKKKEGKKQ) on tumor phenotypes. Our
results showed that P(122-131) inhibits DU145 and
LNCaP cell adhesion, anchorage-independent prolifera-
tion, and migration in a concentration dependent man-
ner. Furthermore, the CAM assay revealed that P(122-
131) suppressed the formation of new blood vessels, a
process important for tumor growth and metastasis.
These biological activities of P(122-131) could be attrib-
uted solely to its high positive charge. Nevertheless, this
does not seem to be the case, since, in the same set of
experiments, neither AAD nor 5K exerted any detect-
able biological activity. Thus, the action of P(122-131) is
more likely due to its specific amino acid sequence and
charge.
To reveal the mechanism through which P(122-131)
exerts its biological actions, we investigated the effect of
this peptide on signaling mediated by the pleiotrophin
receptors. Pleiotrophin binds to specific cell surface
Figure 6 Effect of pleiotrophin or RPTPb/ζ knockdown on P(122-131)-induced kinase signaling. Western blot analysis of phosphorylated
Src, Fak, Pten, and Erk
1/2 in DU145-HM2 (A) and DU145-RM6 cells (B) stimulated with 20 μM P(122-131) for 3 minutes (Src) or 15 minutes (Fak,
Pten, and Erk
1/2). The blots were stripped and reprobed for HSC70. Results are expressed as% change relative to control and are mean values ±
SE from at least 3 independent experiments.
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[12]. RPTPb/ζ is synthesized as a membrane-bound CS
proteoglycan and its extracellular variant, which is gen-
erated by alternative splicing, is phosphacan, a major
soluble CS proteoglycan [12,35]. Pleiotrophin binding to
RPTPb/ζ d e p e n d so nt h eC Sp o r t i o no ft h i sr e c e p t o r ,
and the removal of CS results in a remarkable decrease
in binding affinity [36]. However, treatment of cells with
chondroitinase had no effect on the binding of P(122-
131) to DU145 cells, suggesting that P(122-131) does
not bind to the RPTPb/ζ-derived glycosaminoglycans, in
spite of its basicity [29]. Our results demonstrate that P
(122-131) actions are mediated by RPTPb/ζ. P(122-131)
was co localized with RPTPb/ζ at the cell surface and
eventually become cytoplasmic, likely as a result of
endocytosis. Moreover, immunoprecipitation followed
by Western blotting confirms the interaction between P
(122-131) and RPTPb/ζ [29].
RPTPb/ζ is a receptor phosphatase with intrinsic cata-
lytic activity [30]. In a previous study, we showed that
pleiotrophin/RPTPb/ζ interaction leads to different bio-
logical responses according to RPTPb/ζ substrates.
Pleiotrophin/RPTPb/ζ-Src interaction reduces the phos-
phorylation levels of Src, Fak, Pten, and Erk
1/2, and inhi-
bits cellular adhesion and migration (unpublished data).
Investigation of the transduction mechanism revealed
that P(122-131) induced Src, Fak, and Erk
1/2 inactiva-
tion in a concentration and time-dependent manner.
Furthermore, P(122-131) activated Pten, a tumor sup-
pressor which activity has been proposed to reduce cell
migration and proliferation [37,38].
The finding that the inhibitory effect of P(122-131) on
cellular adhesion and migration could be reduced by
down-regulation of pleiotrophin or RPTPb/ζ expression,
demonstrates that this peptide not only ineracts with
RPTPb/ζ and inhibits cellular adhesion and migration,
but also antagonizes the interaction of pleiotrophin with
its others receptors. P(122-131) interference with other
pleiotrophin receptors was confirmed by the finding that
P(122-131) induced Src and Fak inactivation on cells
with RPTPb/ζ knockdown. Furthermore, we excluded
the possibility of P(122-131) interference with other
growth factors, since the peptide did not exert any bio-
l o g i c a la c t i o no nc e l l st h a tt h ee x p r e s s i o nl e v e l so fb o t h
pleiotrophin and RPTPb/ζ are down-regulated.
Our results also showed that P(122-131) inhibits
anchorage-independent proliferation, but the effect of
RPTPb/ζ knockdown was so strong that we cannot
draw any conclusion about the mechanism through
which the peptide inhibits this biological action. It is
known that RPTPs show structural and functional simi-
larity to CAMs. Although certain RPTPs mediate homo-
philic interactions [39], there are no data indicating that
RPTPb/ζ is implicated in such interactions.
Conclusions
In the context of studying the functions of specific
domains of pleiotrophin and defining peptides with anti
tumor actions, we identified the minimum sequence
responsible for the inhibition of pleiotrophin activity.
Our results demonstrated that P(122-131) interacts with
RPTPb/ζ and triggers a signal transduction pathway that
inhibits DU145 and LNCaP adhesion and migration,
while in parallel antagonizes the interaction of pleiotro-
phin with its others receptors, inhibiting pleiotrophin-
induced biological actions (Figure 7). Cumulatively,
these results indicate that P(122-131) may be a potential
anticancer agent, and they warrant further study of this
peptide.
Methods
Materials
Standard Boc amino acids, p-methylbenzhydrylamine-
polystyrene resin (0.81 mmol NH2/g), and O-(benzotria-
zol-1-yl)-1,1,3,3-tetramethyluronium hexafluoropho-
sphate (HBTU) were purchased from Senn Chemicals.
Solvents (peptide synthesis grade) and other reagents
were obtained from Applied Biosystems. Cell culture
reagents were from BiochromKG (Seromed, Germany).
All other reagents were purchased from Sigma-Aldrich.
Figure 7 Suggested mechanism of P(122-131) action on DU145
cells that express only RPTPb/ζ and N-Syndecan.
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(Tyr925), pPten (Ser380), pAkt (Ser473), and pErk
1/2
(Thr202/Tyr204), as well as monoclonal antibodies
against Src (36D10) were purchased from Cell Signaling
Technology. Polyclonal antibodies against HSC70 were
purchased from Santa Cruz Biotechnology, Inc. Mono-
clonal anti-RPTPb/ζ antibodies were from BD Trans-
duction Laboratories (San Diego, CA), and actin
polyclonal antibody was purchased from Sigma-Aldrich.
Cell culture
The human prostate cancer epithelial cell lines DU145
and LNCaP (ATCC) were grown in RPMI-1640 medium
supplemented with 10% fetal bovine serum (FBS), 100
U/ml penicillin, and 100 μg/ml streptomycin. Cultures
were maintained in 5% CO2 and 100% humidity at 37°C.
Peptide synthesis and characterization
P(122-131) (KKKKKEGKKQ) and B(122-131) [Biot-G4-P
(122-131)] peptides were produced as previously
described, having no cytotoxic effect [29]. The control
peptide (5K) (KKKKK) was purchased from Sigma-
Aldrich (Saint-Quentin Fallavier, France).
Adhesion assay
24-well culture plates were coated with 10 μg/ml fibro-
nectin for 1 h at 37°C. Wells were then incubated with
a 0.5% solution of bovine serum albumin (BSA) for 1 h
at 37°C to block further non specific adsorption of pro-
tein. 50.000 resuspended cells in RPMI-1640 medium
supplemented with 2.5% FBS were then seeded. After a
10-min incubation period unattached cells were
removed by shaking the plates at 2.000 rpm for 10 sec,
and by three washes with PBS. Attached cells were fixed
with 4% paraformaldehyde and stained with crystal
violet.
Crystal Violet assay
Adherent cells were fixed with methanol and stained
with 0.5% crystal violet in 20% methanol for 20 min.
After gentle rinsing with water, the retained dye was
extracted with 30% acetic acid, and the absorbance was
measured at 590 nm.
Soft agar growth assay
Anchorage-independent growth was assessed by measur-
ing the formation of colonies in soft agar. Twelve-well
plates were layered with bottom agar, which consisted
of growth medium containing 10% FBS and 0.8% agar.
After the bottom agar had solidified, 2000 cells were
resuspended in growth medium containing 10% FBS,
0.3% agar, and peptide, then seeded onto the bottom
agar. The top agar was then allowed to solidify, and
standard growth media supplemented with peptide was
added to each well. The cells were incubated at 37°C, in
5% CO2 for 12 days. Cell colonies larger than 50 μm
were quantified by counting the entire area of each well.
Transwell assay
Migration assays were performed in Boyden chambers
using filters (8 μm pore size, Costar, Avon, France)
coated with fibronectin (7,5 μg/cm
2) for 1 h at 37°C. Fil-
ters were washed, blocked with 0.5% BSA for 1 h at 37°
C, and dried. Assay medium (RPMI-1640 medium sup-
plemented with 2.5% FBS, and 0.5% BSA, with or with-
out the chemo attractant) was added to the lower
compartment, and 10
4 cells were added into the insert.
After incubation for 30 min at 37°C, filters were fixed.
Non-migrated cells were scrapped off the upper side of
the filter, and filters were stained with crystal violet.
Number of migrated cells was quantified by counting
the entire area of the filter.
Chicken embryo chorioallantoic membrane (CAM) assay
The in vivo C A Ma n g i o g e n e s i sm o d e lw a su s e da sp r e -
viously detailed [10].
Immunofluorescence confocal microscopy
DU145 cells grown in 8-well tissue culture slides (Nunc)
were incubated with 100 μΜ biotinylated P(122-131) (B
(122-131)) or with pleiotrophin at 4°C for the indicated
time. The cells were then fixed in 4% paraformaldehyde
for 10 min at room temperature, rinsed three times with
PBS, quenched with 50 mM Tris buffer pH 8.0 and 100
mM NaCl, permeabilized for 15 min in PBS containing
0.3% Triton X-100 and 0.5% bovine serum albumin
(BSA), and blocked in PBS containing 3% BSA for 1 h
at room temperature. Cells were incubated for 1 h with
streptavidin-FITC (1:100), anti-RPTPb/ζ antibody
(1:100), and rhodamine-conjugated goat anti-mouse IgG
(1:600) in permeabilization buffer. After three rinses in
PBS, cells were mounted using Sigma mounting fluid.
Labelling was observed using a Nikon confocal micro-
scope and photographed.
Reverse transcriptase-polymerase chain reaction (RT-PCR)
for RPTPb/ζ, pleiotrophin, and GAPDH
Total RNA was extracted using the Nucleospin RNA II
kit (Macherey-Nagel, Germany), according to the manu-
facturer’s instructions. The integrity of he isolated RNA
was examined by electrophoresis on a 1% agarose gel
containing 0.5 mg/ml ethidium bromide. Specific pri-
mers were as follows: hRPTPb/ζ,5 ′′-TTCTGT
GCTCTGACAACCCTTA-3′′ and 5′′-AGGAAGAG-
GAAAACAATGCTCA-3′′; hpleiotrophin, 5′′-GAGCGC-
CAGAGAGGACGTTT-3′′ and 5′′-TCCTGTTTGCTGA
TGTCCTTTT-3′′ hGAPDH, 5′′-CCACCCATGG-
CAAATTCCATGGCA-3′′ and 5′
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PCR reactions were performed in a single step with 250
ng of total RNA, using the Qiagen RT-PCR system. The
RT-PCR products were subjected to electrophoresis on
1% agarose gel containing 0.5 mg/ml ethidium bromide,
digitally photographed, and quantified using image ana-
lysis software (Scion Image PC, Scion Corporation, Fre-
derick, MD).
Pleiotrophin-antisense RNA transfection
Stable transfection of DU145 to down-regulate pleiotro-
phin expression was performed as previously described
[23]. Briefly, full length cDNA for pleiotrophin was sub-
cloned at EcoRI site in pcDNA3.1+ expression vector
(In Vitrogen, Cergy Pontoise, France) in antisense orien-
tation. DU145 cells were seeded in RPMI-1640 medium
supplemented with 10% FBS. 24 h later, cells were trans-
fected with the Transfast™ Reagent (Promega Corpera-
tion) according to the manufacturer’s instructions. The
ratio of Transfast™ Reagent to DNA was 2:1. After 1
month of selection with 300 μg/ml G418, clones were
screened for down-regulation of pleiotrophin expression.
The pcDNA3.1+ expression vector was used as a nega-
tive control.
siRNA transfection
RNA oligonucleotide primers and the siPORT NeoFX
Transfection Agent were obtained from Ambion Inc.
The following sequences were used: siRNA1 RPTPb/ζ
sense, 5′′-AAAUGCGAAUCCUAAAGCGUU-3′′;
siRNA1 RPTPb/ζ antisense, 5′′-AACGCUUUAG-
GAUUCGCAUUU-3′′,s i R N A 2R P T P b/ζ sense 5′
′-GCGACCAACUGAUUGUCGGA-3′′;s i R N A 2R P T P b/
ζ antisense, 5′′-UCGACAAUCAGUUGGUCGC-3′′.T h e
annealing of the primers and the transfection was per-
formed according to Ambion’s instructions. Briefly,
siPORT NeoFX and siRNA were mixed at a final ratio
of 1:10 in OPTI-MEM media. The transfection com-
plexes were then overlaid onto 6-well plate cultures
grown in RPMI-1640 supplemented with 10% FBS.
Transfection efficiency was evaluated using Silencer
FAM Labelled GAPDH siRNA (Ambion). Negative con-
trol siRNAs from Ambion was also used.
shRNA transfection
Stable transfection of DU145 cells using shRNA target-
ing RPTPb/ζ expression was performed using the pSi-
lencer 4.1-CMV expression vector and the siPORT XP-1
Transfection Agent obtained from Ambion Inc. Based
on the siRNA sequence, shRNA was designed, ligated
into the pSilencer 4.1-CMV expression vector and trans-
fected into cells according to Ambion’s instructions.
B r i e f l y ,s i P O R TX P - 1a n ds h R N Aw e r em i x e da taf i n a l
ratio of 1:6 in OPTI-MEM media. The transfection
complexes were then overlaid onto 24-well plate cul-
tures grown in RPMI-1640 supplemented with 10% FBS.
After 1 month of selection with 300 μg/ml G418, clones
were screened for down-regulation of RPTPb/ζ expres-
sion. Double-stranded negative control shRNA from
Ambion was also used.
Immunoprecipitation
Media from DU145 cultures grown in 60 mm plastic
dishes were aspirated, cells were washed twice with ice-
cold PBS, and cells were lysed in 1 ml buffer containing
50 mM HEPES pH 7.0, 150 mM NaCl, 10 mM EDTA,
1% Triton X-100, 1% Nonidet P-40, 1 mM phenyl-
methylsulfonyl fluoride, 1 mM sodium orthovanadate, 5
μg/ml aprotinin, and 5 μg/ml leupeptin. Cells were har-
vested, sonicated for 4 min on ice, and centrifuged at
20.000 g for 10 min at 4°C. Approximately 400 μgo f
the supernatant was then incubated with 30 μlo fp r o -
tein A-Sepharose bead suspension for 60 min at room
temperature. Beads were collected by centrifugation, and
the supernatants were incubated overnight at 4°C with
anti-RPTPb/ζ (1:200) or anti-Src (1:1000) primary anti-
bodies. The mixtures were then incubated with 80 μl
protein A-Sepharose beads for 3 h at 4°C. The beads
and bound proteins were collected by centrifugation
(10.000 g, 4°C), washed three times with ice-cold lysis
buffer, and resuspended in 60 μl 2× SDS loading buffer
(100 mM Tris-HCl pH 6.8, 4% SDS, 0.2% bromphenol
blue, 20% glycerol, 0.1 M dithiothreitol). Samples were
then heated to 95-100°C for 5 min and centrifuged. Fifty
microliters of the supernatant were analyzed by Western
blotting.
Western blot analysis
Cells were starved for 4 h, then incubated with P(122-
131) for varying times. Cells were subsequently washed
twice with PBS and lysed in 250 μl 2× SDS loading buf-
fer under reducing conditions. Proteins were separated
by SDS-PAGE and transferred to an Immobilon-P mem-
brane for 3 h in 48 mM Tris pH 8.3, 39 mM glycine,
0.037% SDS, and 20% methanol. The membrane was
blocked in TBS containing 5% non-fat milk and 0.1%
Tween 20 for 1 h at 37°C. Membranes were then probed
with primary antibody overnight at 4°C under continu-
ous agitation. Anti-RPTPb/ζ a n t i b o d yw a su s e da ta
1:500 dilution. All other antibodies were used at a
1:1000 dilution. The blot was then incubated with the
appropriate secondary antibody coupled to horseradish
peroxidase, and bands were detected with the ChemiLu-
cent Detection System Kit (Chemicon International Inc.,
CA), according to the manufacturer’s instructions.
Where indicated, blots were stripped in buffer contain-
ing 62.5 mM Tris HCl pH 6.8, 2% SDS, 100 mM 2-mer-
captoethanol for 30 min at 50°C and reprobed.
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performed through analysis of digital images using the
ImagePC image analysis software (Scion Corporation,
Frederick, MD).
Statistical analysis
Comparisons of the mean values among groups was per-
formed by means of ANOVA and unpaired Student t-
test. Homogeneity of variances was tested by Levene’s
test. Each experiment included at least triplicate mea-
surements for each condition tested. All results are
expressed as mean ± SE. from at least three independent
experiments. Values of p less than 0.05 were accepted as
significant (*p < 0.05, **p < 0.01, ***p < 0.001).
Additional material
Additional file 1: A) Antisense RNA-mediated pleiotrophin
knockdown in DU145 cells. Western blot analysis (WB) and RT-PCR
analysis for pleiotrophin. DU145-NC1 and DU145-NC3 cells transfected
with pcDNA3.1+ plasmid. DU145-HM2 and DU145-HM5 cells transfected
with pleiotrophin antisense RNA. (B) siRNA-mediated RPTPb/ζ
knockdown in DU145-HM2 cells. Western blot analysis (WB) and RT-
PCR analysis for pleiotrophin and RPTPb/ζ. siRNA NC siRNA negative
control sequence that do not target any known mRNA.
Acknowledgements
This work was partially supported by grants from ELKE, University of Patras
(Kartheodoris), from ANR (ANR-06-RIB016-02), from INCA (PL06-093) and by
the Centre National de la Recherche Scientifique.
Author details
1Division of Genetics, Cell and Developmental Biology, Department of
Biology, University of Patras, Greece.
2Laboratoire de recherche sur la
Croissance Cellulaire, la Réparation et la Régénération Tissulaires (CRRET),
CNRS UMR 7149, Université Paris XII, Avenue du Général de Gaulle, 94010
Créteil Cedex, France.
Authors’ contributions
All authors participated in the design of the study. ZD performed all
experiments and drafted the manuscript. All authors read, revised, and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 29 January 2010 Accepted: 25 August 2010
Published: 25 August 2010
References
1. Rauvala H: An 18-kd heparin-binding protein of developing brain that is
distinct from fibroblast growth factors. EMBO J 1989, 8:2933-2941.
2. Fang W, Hartmann N, Chow DT, Riegel AT, Wellstein A: Pleiotrophin
stimulates fibroblasts and endothelial and epithelial cells and is
expressed in human cancer. J Biol Chem 1992, 267:25889-25897.
3. Soulie P, Heroult M, Bernard-Pierrot I, Caruelle D, Oglobine J, Barritault D,
Courty J: Correlation of elevated plasma levels of two structurally related
growth factors, heparin affin regulatory peptide and midkine, in
advanced solid tumor patients. Cancer Detect Prev 2004, 28:319-324.
4. Souttou B, Juhl H, Hackenbruck J, Rockseisen M, Klomp HJ, Raulais D,
Vigny M, Wellstein A: Relationship between serum concentrations of the
growth factor pleiotrophin and pleiotrophin-positive tumors. J Natl
Cancer Inst 1998, 90:1468-1473.
5. Chauhan AK, Li YS, Deuel TF: Pleiotrophin transforms NIH 3T3 cells and
induces tumors in nude mice. Proc Natl Acad Sci USA 1993, 90:679-682.
6. Choudhuri R, Zhang HT, Donnini S, Ziche M, Bicknell R: An angiogenic role
for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer
Res 1997, 57:1814-1819.
7. Bowden ET, Stoica GE, Wellstein A: Anti-apoptotic signaling of
pleiotrophin through its receptor, anaplastic lymphoma kinase. J Biol
Chem 2002, 277:35862-35868.
8. Courty J, Dauchel MC, Caruelle D, Perderiset M, Barritault D: Mitogenic
properties of a new endothelial cell growth factor related to
pleiotrophin. Biochem Biophys Res Commun 1991, 180:145-151.
9. Czubayko F, Riegel AT, Wellstein A: Ribozyme-targeting elucidates a direct
role of pleiotrophin in tumor growth. J Biol Chem 1994, 269:21358-21363.
10. Papadimitriou E, Polykratis A, Courty J, Koolwijk P, Heroult M, Katsoris P:
HARP induces angiogenesis in vivo and in vitro: implication of N or C
terminal peptides. Biochem Biophys Res Commun 2001, 282:306-313.
11. Raulo E, Chernousov MA, Carey DJ, Nolo R, Rauvala H: Isolation of a
neuronal cell surface receptor of heparin binding growth-associated
molecule (HB-GAM). Identification as N-syndecan (syndecan-3). J Biol
Chem 1994, 269:12999-13004.
12. Maeda N, Nishiwaki T, Shintani T, Hamanaka H, Noda M: 6B4 proteoglycan/
phosphacan, an extracellular variant of receptor-like protein-tyrosine
phosphatase zeta/RPTPbeta, binds pleiotrophin/heparin-binding growth-
associated molecule (HB-GAM). J Biol Chem 1996, 271:21446-21452.
13. Stoica GE, Kuo A, Aigner A, Sunitha I, Souttou B, Malerczyk C, Caughey DJ,
Wen D, Karavanov A, Riegel AT, Wellstein A: Identification of anaplastic
lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol
Chem 2001, 276:16772-16779.
14. Grzelinski M, Bader N, Czubayko F, Aigner A: Ribozyme-targeting reveals
the rate-limiting role of pleiotrophin in glioblastoma. Int J Cancer 2005,
117:942-951.
15. Lu KV, Jong KA, Kim GY, Singh J, Dia EQ, Yoshimoto K, Wang MY,
Cloughesy TF, Nelson SF, Mischel PS: Differential induction of
glioblastoma migration and growth by two forms of pleiotrophin. J Biol
Chem 2005, 280:26953-26964.
16. Polykratis A, Katsoris P, Courty J, Papadimitriou E: Characterization of
heparin affin regulatory peptide signaling in human endothelial cells. J
Biol Chem 2005, 280:22454-22461.
17. Powers C, Aigner A, Stoica GE, McDonnell K, Wellstein A: Pleiotrophin
signaling through anaplastic lymphoma kinase is rate-limiting for
glioblastoma growth. J Biol Chem 2002, 277:14153-14158.
18. Ulbricht U, Eckerich C, Fillbrandt R, Westphal M, Lamszus K: RNA
interference targeting protein tyrosine phosphatase zeta/receptor-type
protein tyrosine phosphatase beta suppresses glioblastoma growth in
vitro and in vivo. J Neurochem 2006, 98:1497-1506.
19. Dean RA, Butler GS, Hamma-Kourbali Y, Delbe J, Brigstock DR, Courty J,
Overall CM: Identification of candidate angiogenic inhibitors processed
by matrix metalloproteinase 2 (MMP-2) in cell-based proteomic screens:
disruption of vascular endothelial growth factor (VEGF)/heparin affin
regulatory peptide (pleiotrophin) and VEGF/Connective tissue growth
factor angiogenic inhibitory complexes by MMP-2 proteolysis. Mol Cell
Biol 2007, 27:8454-8465.
20. Polykratis A, Delbe J, Courty J, Papadimitriou E, Katsoris P: Identification of
heparin affin regulatory peptide domains with potential role on
angiogenesis. Int J Biochem Cell Biol 2004, 36:1954-1966.
21. Heroult M, Bernard-Pierrot I, Delbe J, Hamma-Kourbali Y, Katsoris P,
Barritault D, Papadimitriou E, Plouet J, Courty J: Heparin affin regulatory
peptide binds to vascular endothelial growth factor (VEGF) and inhibits
VEGF-induced angiogenesis. Oncogene 2004, 23:1745-1753.
22. Gronberg H: Prostate cancer epidemiology. Lancet 2003, 361:859-864.
23. Hatziapostolou M, Delbe J, Katsoris P, Polytarchou C, Courty J,
Papadimitriou E: Heparin affin regulatory peptide is a key player in
prostate cancer cell growth and angiogenicity. Prostate 2005, 65:151-158.
24. Vacherot F, Caruelle D, Chopin D, Gil-Diez S, Barritault D, Caruelle JP,
Courty J: Involvement of heparin affin regulatory peptide in human
prostate cancer. Prostate 1999, 38:126-136.
25. Bernard-Pierrot I, Delbe J, Rouet V, Vigny M, Kerros ME, Caruelle D,
Raulais D, Barritault D, Courty J, Milhiet PE: Dominant negative effectors of
heparin affin regulatory peptide (HARP) angiogenic and transforming
activities. J Biol Chem 2002, 277:32071-32077.
Diamantopoulou et al. Molecular Cancer 2010, 9:224
http://www.molecular-cancer.com/content/9/1/224
Page 12 of 1326. Zhang N, Zhong R, Wang ZY, Deuel TF: Human breast cancer growth
inhibited in vivo by a dominant negative pleiotrophin mutant. J Biol
Chem 1997, 272:16733-16736.
27. Zhang N, Zhong R, Deuel TF: Domain structure of pleiotrophin required
for transformation. J Biol Chem 1999, 274:12959-12962.
28. Bernard-Pierrot I, Delbe J, Caruelle D, Barritault D, Courty J, Milhiet PE: The
lysine-rich C-terminal tail of heparin affin regulatory peptide is required
for mitogenic and tumor formation activities. J Biol Chem 2001,
276:12228-12234.
29. Bermek O, Diamantopoulou Z, Polykratis A, Dos SC, Hamma-Kourbali Y,
Burlina F, Delbe J, Chassaing G, Fernig DG, Katsoris P, Courty J: A basic
peptide derived from the HARP C-terminus inhibits anchorage-
independent growth of DU145 prostate cancer cells. Exp Cell Res 2007,
313:4041-4050.
30. Meng K, Rodriguez-Pena A, Dimitrov T, Chen W, Yamin M, Noda M,
Deuel TF: Pleiotrophin signals increased tyrosine phosphorylation of beta
beta-catenin through inactivation of the intrinsic catalytic activity of the
receptor-type protein tyrosine phosphatase beta/zeta. Proc Natl Acad Sci
USA 2000, 97:2603-2608.
31. Roskoski R Jr: Src protein-tyrosine kinase structure and regulation.
Biochem Biophys Res Commun 2004, 324:1155-1164.
32. Kilpelainen I, Kaksonen M, Kinnunen T, Avikainen H, Fath M, Linhardt RJ,
Raulo E, Rauvala H: Heparin-binding growth-associated molecule contains
two heparin binding beta-sheet domains that are homologous to the
thrombospondin type I repeat. J Biol Chem 2000, 275:13564-70.
33. Papadimitriou E, Heroult M, Courty J, Polykratis A, Stergiou C, Katsoris P:
Endothelial cell proliferation induced by HARP: implication of N or C
terminal peptides. Biochem Biophys Res Commun 2000, 274:242-248.
34. Bohlen P, Muller T, Gautschi-Sova P, Albrecht U, Rasool CG, Decker M,
Seddon A, Fafeur V, Kovesdi I, Kretschmer P: Isolation from bovine brain
and structural characterization of HBNF, a heparin-binding neurotrophic
factor. Growth Factors 1991, 4:97-107.
35. Milev P, Chiba A, Haring M, Rauvala H, Schachner M, Ranscht B, Margolis RK,
Margolis RU: High affinity binding and overlapping localization of
neurocan and phosphacan/protein-tyrosine phosphatase-zeta/beta with
tenascin-R, amphoterin, and the heparin-binding growth-associated
molecule. J Biol Chem 1998, 273:6998-7005.
36. Maeda N, He J, Yajima Y, Mikami T, Sugahara K, Yabe T: Heterogeneity of
the chondroitin sulfate portion of phosphacan/6B4 proteoglycan
regulates its binding affinity for pleiotrophin/heparin binding growth-
associated molecule. J Biol Chem 2003, 278:35805-35811.
37. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM: Inhibition of
cell migration, spreading, and focal adhesions by tumor suppressor
PTEN. Science 1998, 280:1614-1617.
38. Weng LP, Brown JL, Eng C: PTEN coordinates G(1) arrest by down-
regulating cyclin D1 via its protein phosphatase activity and up-
regulating p27 via its lipid phosphatase activity in a breast cancer
model. Hum Mol Genet 2001, 10:599-604.
39. Peles E, Schlessinger J, Grumet M: Multi-ligand interactions with receptor-
like protein tyrosine phosphatase beta: implications for intercellular
signaling. Trends Biochem Sci 1998, 23:121-124.
doi:10.1186/1476-4598-9-224
Cite this article as: Diamantopoulou et al.: A Pleiotrophin C-terminus
peptide induces anti-cancer effects through RPTPb/ζ. Molecular Cancer
2010 9:224.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Diamantopoulou et al. Molecular Cancer 2010, 9:224
http://www.molecular-cancer.com/content/9/1/224
Page 13 of 13